Related Experiment Video
Updated: Jul 28, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Historical perspective on the treatment of essential thrombocythemia and polycythemia vera
1Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract:
Since 1970, the treatment of essential thrombocythemia (ET) and polycythemia vera (PV) has evolved from alkylating agents to hydroxyurea (HU), and more recently to agents such as interferon-alpha (IFN) and anagrelide. While the earlier treatments for ET and PV have been successful in varying degrees, diagnosis of these disorders is being made earlier and in populations deemed at lower risk, but who may suffer greatly from the toxicity of long-term treatment with these agents. Thus, the risks and benefits of treatment versus nontreatment and between types of therapy have created a need for treatments that are safer for more people for greater lengths of time.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Erythropoiesis
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Venous Thrombosis III: Interprofessional Care

